Teppei Hagino

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 39

Top Topics

Replacement Therapy

Clinical Practice

Juvenile Idiopathic Arthritis

Top Venues

The Journal of dermatology

The Journal of dermatological treatment

Journal of clinical medicine

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Clinical drug investigation (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Clinical drug investigation 44 (4) (2024)
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Marina Onda, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of deucravacitinib for genital, nail, and scalp lesions with psoriasis: a 24-week real-world study. Clinical and experimental dermatology (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis. Dermatitis : contact, atopic, occupational, drug (2024)
Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study. The Journal of dermatology 51 (5) (2024)
Risa Hamada, Yoko Funasaka, Hidehisa Saeki, Naotaka Serizawa, Teppei Hagino, Yumiko Yano, Hiroshi Mitsui, Naoko Kanda
Author reply to the letter regarding 'Dietary habits in adult Japanese patients with vitiligo'. The Journal of dermatology (2024)
Risa Hamada, Yoko Funasaka, Hidehisa Saeki, Naotaka Serizawa, Teppei Hagino, Yumiko Yano, Hiroshi Mitsui, Naoko Kanda
Dietary habits in adult Japanese patients with vitiligo. The Journal of dermatology (2024)
Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Risa Hamada, Yoko Funasaka, Hidehisa Saeki, Naotaka Serizawa, Teppei Hagino, Yumiko Yano, Hiroshi Mitsui, Naoko Kanda
Dietary habits in adult Japanese patients with vitiligo. The Journal of dermatology 51 (4) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study. The Journal of dermatology (2024)
Risa Hamada, Yoko Funasaka, Hidehisa Saeki, Naotaka Serizawa, Teppei Hagino, Yumiko Yano, Hiroshi Mitsui, Naoko Kanda
Dietary habits in adult Japanese patients with vitiligo. The Journal of dermatology 51 (4) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Clinical drug investigation 44 (4) (2024)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Marina Onda, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study. The Journal of dermatology (2024)
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis. The Journal of dermatological treatment 35 (1) (2024)
Teppei Hagino, Hidehisa Saeki, Naoko Kanda
Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis. Journal of clinical medicine 12 (3) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. The Journal of dermatology (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. Journal of clinical medicine 12 (5) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. The Journal of dermatological treatment 34 (1) (2023)
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. The Journal of dermatological treatment 34 (1) (2023)
Teppei Hagino, Risa Hamada, Mai Yoshida, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. Clinical, cosmetic and investigational dermatology 16 (2023)
Teppei Hagino, Mai Yoshida, Risa Hamada, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda
Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. The Journal of dermatology (2023)
Teppei Hagino, Hidehisa Saeki, Naoko Kanda
Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis. Journal of clinical medicine 12 (3) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. Journal of clinical medicine 12 (5) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. Journal of clinical medicine 12 (5) (2023)
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis. The Journal of dermatological treatment 35 (1) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis. Journal of clinical medicine 12 (6) (2023)
Teppei Hagino, Hidehisa Saeki, Naoko Kanda
Two cases of generalized pustular psoriasis successfully treated with bimekizumab. The Journal of dermatology (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis. Journal of clinical medicine 12 (6) (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. The Journal of dermatology (2023)
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis. Journal of clinical medicine 12 (6) (2023)
Teppei Hagino, Hidehisa Saeki, Naoko Kanda
The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. The Journal of dermatology 49 (11) (2022)
Teppei Hagino, Hajime Nakano, Hidehisa Saeki, Naoko Kanda
A Case of Darier's Disease with a Novel Missense Mutation in ATP2A2 Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound Ointment. Clinical, cosmetic and investigational dermatology 15 (2022)